WILMINGTON, DE — Incyte (Nasdaq: INCY) has named Bill Meury as its new President and Chief Executive Officer (CEO) and elected him to the company’s Board of Directors, effective immediately. Meury succeeds Hervé Hoppenot, who will retire after 11 years of leadership but remain as an advisor to the CEO and a Board member until the end of 2025 to ensure a smooth transition. Julian Baker, previously Lead Independent Director, has also been elected as Chairman of the Board.
Meury, a seasoned executive with more than 30 years of experience in the pharmaceutical industry, joins with a proven track record in organizational strategy, pipeline development, and commercial operations. He most recently served as CEO of Anthos Therapeutics, where he positioned the company for its next phase of growth. Prior to that, he helmed Karuna Therapeutics and held senior leadership roles at Allergan, managing a portfolio of 50 products generating $16 billion in revenue.
“I am honored to join Incyte at this pivotal moment and thank Hervé for his support during this transition,” said Meury. “My priority is to build upon our exceptional R&D and commercial capabilities to accelerate new product flow, drive sustainable growth and create value for all stakeholders. I look forward to working with the team to continue to grow the company for enduring success.”
Under Hervé Hoppenot’s leadership since 2014, Incyte transformed from a U.S.-focused, single-product company into a global organization with a robust portfolio of six novel medicines and revenues that grew from $355 million to $4.2 billion. “It has been a privilege to lead Incyte over the past eleven years,” said Hoppenot. “I am retiring at a time when the company has its strongest management team, R&D pipeline, and commercial portfolio. With Bill’s leadership, I am confident that the company will continue its legacy of delivering transformative solutions to patients.”
Julian Baker, the newly appointed Chairman of the Board, praised Meury’s qualifications and the thoughtful approach to succession planning that led to his appointment. “Bill is a decisive and collaborative leader whose ability to translate scientific breakthroughs into business results is exactly what we need to accelerate the company’s growth,” said Baker. “I look forward to partnering with him to create long-term value for our shareholders.”
Meury’s arrival marks a critical moment for the company as it continues to lead in oncology and immunology while expanding its pipeline and capabilities. With headquarters in Wilmington, Delaware, and operations across Europe, Japan, and Canada, the company is well-positioned for future growth under its new leadership.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.